Although this approach is key to more durable therapeutic effects for BCC, MB and most likely also AML patients, SMO-independent GLI activation remains a major limitation for the successful use of SMO antagonists that needs to be overcome for the therapy of a number of malignancies with high medical need. Here, SMO is linked to skin basal cell carcinoma.